menu
    • menu
    [{"orgOrder":0,"company":"Shanghai HEP Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Hepalatide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai HEP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai HEP Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai HEP Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai HEP Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Hepalatide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai HEP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai HEP Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai HEP Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai HEP Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Hepalatide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai HEP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai HEP Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai HEP Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai HEP Pharmaceutical","sponsor":"Shanghai Tong Ren Hospital | Shanghai East Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Hepalatide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai HEP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai HEP Pharmaceutical \/ Shanghai Tong Ren Hospital | Shanghai East Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai HEP Pharmaceutical \/ Shanghai Tong Ren Hospital | Shanghai East Hospital"},{"orgOrder":0,"company":"Shanghai HEP Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Hepalatide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai HEP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai HEP Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai HEP Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai HEP Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Hepalatide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai HEP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai HEP Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai HEP Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai HEP Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Hepalatide","moa":"Bile acid transporter","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Shanghai HEP Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai HEP Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai HEP Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Shanghai HEP Pharmaceutical

    Menu

    Shanghai HEP Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D

                            Details : Hepalatide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis D.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 17, 2024

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Hepalatide in Chronic Hepatitis D(CHD) Patients

                            Details : Hepalatide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis D.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 24, 2023

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Shanghai Tong Ren Hospital | Shanghai East Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients

                            Details : Hepalatide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 17, 2022

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Shanghai Tong Ren Hospital | Shanghai East Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin

                            Details : Hepalatide is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 10, 2020

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

                            Details : Hepalatide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 11, 2020

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers

                            Details : Hepalatide is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 18, 2017

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed

                            Shanghai HEP Pharmaceutical

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers

                            Details : Hepalatide is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 23, 2015

                            Lead Product(s) : Hepalatide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth